Pembrolizumab plus chemo for advanced EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of pembrolizumab (an immunotherapy) and chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation (exon 21) and a PD-L1 score of 1% or higher. It aims to see if this combination can help shrink tumors and improve outcomes for those who have not yet received any anticancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have stage IV non-squamous non-small cell lung cancer (a type of lung cancer that has spread).
- You have not had any prior treatment with targeted therapy, chemotherapy, or immunotherapy.
- Your tumor has an EGFR exon 21 mutation and a PD-L1 score of 1% or higher.
- You are able to do daily activities (like walking or light work) without help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This trial tests if removing the main lung tumor followed by the targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer. It is for those who have not had prior treatment and are healthy enough for surgery.
This trial tests a new drug, befotertinib, combined with chemotherapy as a first treatment for advanced lung cancer with an EGFR mutation. It aims to see if this approach can improve outcomes and uses a special blood test to guide treatment adjustments.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.